secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOLIFE SOLUTIONS INC (BLFS)
CIK:        0000834365
Form:       8-K
Filed at:   2025-11-06T23:59:59+00:00
Accession:  0001628280-25-050163
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioLife Q3 total rev $28.1M (+31% YoY); net income $0.6M; raises cell processing guidance to $93-94M
--------------------------------------------------------------------------------

- Total Q3 revenue $28.1M (up 31% YoY); Cell Processing revenue $25.4M (up 33% YoY).
- GAAP net income $0.6M vs loss $0.5M in Q3 2024; adjusted EBITDA $7.8M (28% of revenue).
- Full-year Cell Processing revenue guidance raised to $93-94M (from $91-93M); total rev $95-96M excl. evo.
- Completed sale of evo cold chain logistics on Oct 6 for $25.5M cash, streamlining to pure-play cell processing.
- Cash and marketable securities $98.4M as of Sep 30; no evo proceeds included.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/834365/000162828025050163/0001628280-25-050163-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/834365/000162828025050163/blfs-20251106.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-050163

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer